| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: AEGN |
| Security Type |
Common Stock |
| Lead Underwriter |
Chase H&Q |
| Days In Registration |
77 |
| Date Filed |
25-Aug-2000 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2007) |
| Industry |
Manufacturing |
| Business Description |
Develop products for the controlled delivery of drugs to the lungs, which is called pulmonary drug delivery; drugs can be delivered via a fine mist, or aerosol, to the lungs to treat breathing-related conditions such as asthma, or through the lungs to the bloodstream to treat diseases or conditions outside of the lungs such as diabetes |
| Revenue |
$5.8M |
| Net Income |
-$16.9M |
| Shares Outstanding (post-offering) |
19.38M |
| Chairman and CEO |
Jane E. Shaw |
| Number of Employees |
96 |
|
| Original Filing Information |
| US |
| Shares Filed |
3.6M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
3.6M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
540.0K |
| File Amount |
$50.4M |
| File Price Range |
$15.00 - $13.00 |
| File Mid Price |
$14.00 |
Current Filing Information
(Amended 9-Nov-2000) |
|
US |
|
Shares Filed |
3.6M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
3.6M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$50.4M |
| · % Change from Original |
0.0 |
| File Price Range |
$15.00 - $13.00 |
| File Mid Price |
$14.00 |
|
